20 February 2024
20 February 2024
The Phase II trial for amyotrophic lateral sclerosis (ALS) therapy failed to show improvement in ALS functional rating scale.
The trial is designed to establish the safety and tolerability of varying doses of CK0803 in patients with amyotrophic lateral sclerosis (ALS).
The multicentre, single-arm trial in the US is designed to assess the efficacy and safety of the therapy in the patients.
The company is preparing to file a new drug application (NDA) with China's National Medical Products Administration (NMPA) for IBI311 to treat thyroid eye disease (TED).
To execute the initiative, Innovative Trials partnered with the Oliver Patch Project.
An FDA approval in late 2024 would make it the first TROP2-directed therapy for non-small cell lung cancer (NSCLC) antibody drug conjugate patients.
Applied plans to submit a new drug application following the announcement of positive interim data from its Phase III trial.
Tina is an AI assistant who takes patients through cognitive tests which help clinicians understand the rate of disease progression.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
